Drug
Descovy
Descovy is a pharmaceutical drug with 5 clinical trials. Currently 1 active trials ongoing. Historical success rate of 100.0%.
Total Trials
5
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 4 completed trials
Completion Rate
100%(4/4)
Active Trials
1(20%)
Results Posted
50%(2 trials)
Phase Distribution
Ph phase_3
2
40%
Ph phase_4
1
20%
Ph phase_2
1
20%
Phase Distribution
0
Early Stage
1
Mid Stage
3
Late Stage
Phase Distribution4 total trials
Phase 2Efficacy & side effects
1(25.0%)
Phase 3Large-scale testing
2(50.0%)
Phase 4Post-market surveillance
1(25.0%)
Highest Phase Reached
Phase 4Trial Status & Enrollment
Completion Rate
100.0%
4 of 4 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
1
trials recruiting
Total Trials
5
all time
Status Distribution
Active(1)
Completed(4)
Detailed Status
Completed4
Active, not recruiting1
Development Timeline
Analytics
Development Status
Total Trials
5
Active
1
Success Rate
100.0%
Most Advanced
Phase 4
Trials by Phase
Phase 21 (25.0%)
Phase 32 (50.0%)
Phase 41 (25.0%)
Trials by Status
completed480%
active_not_recruiting120%
Recent Activity
1 active trials
Showing 5 of 5
completedphase_4
Telehealth as a Modality to Increase the Uptake of PrEP Services in Black and Latino: "e-PrEP"
NCT05528653
active_not_recruiting
Express Testing and Same-day Initiation of PrEP Study
NCT05690815
completedphase_3
Dual Therapy With Boosted Darunavir + Dolutegravir
NCT02486133
completedphase_2
Doravirine Concentrations and Antiviral Activity in Genital Fluids in HIV-1 Infected Individuals
NCT04097925
completedphase_3
Doravirine Concentrations and Antiviral Activity in Cerebrospinal Fluid in HIV-1 Infected Individuals
NCT04079452
Clinical Trials (5)
Showing 5 of 5 trials
NCT05528653Phase 4
Telehealth as a Modality to Increase the Uptake of PrEP Services in Black and Latino: "e-PrEP"
NCT05690815
Express Testing and Same-day Initiation of PrEP Study
NCT02486133Phase 3
Dual Therapy With Boosted Darunavir + Dolutegravir
NCT04097925Phase 2
Doravirine Concentrations and Antiviral Activity in Genital Fluids in HIV-1 Infected Individuals
NCT04079452Phase 3
Doravirine Concentrations and Antiviral Activity in Cerebrospinal Fluid in HIV-1 Infected Individuals
All 5 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 5